IDYA
Price
$21.10
Change
-$0.00 (-0.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1.85B
67 days until earnings call
REGN
Price
$483.07
Change
-$1.86 (-0.38%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
52.15B
56 days until earnings call
Interact to see
Advertisement

IDYA vs REGN

Header iconIDYA vs REGN Comparison
Open Charts IDYA vs REGNBanner chart's image
IDEAYA Biosciences
Price$21.10
Change-$0.00 (-0.00%)
Volume$15.76K
Capitalization1.85B
Regeneron Pharmaceuticals
Price$483.07
Change-$1.86 (-0.38%)
Volume$15.78K
Capitalization52.15B
IDYA vs REGN Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. REGN commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and REGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (IDYA: $21.08 vs. REGN: $483.07)
Brand notoriety: IDYA: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 45% vs. REGN: 130%
Market capitalization -- IDYA: $1.85B vs. REGN: $52.15B
IDYA [@Biotechnology] is valued at $1.85B. REGN’s [@Biotechnology] market capitalization is $52.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 4 bearish.
  • REGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than REGN.

Price Growth

IDYA (@Biotechnology) experienced а +5.14% price change this week, while REGN (@Biotechnology) price change was -20.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

REGN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($52.2B) has a higher market cap than IDYA($1.85B). IDYA YTD gains are higher at: -17.977 vs. REGN (-31.735). REGN has higher annual earnings (EBITDA): 5.53B vs. IDYA (-356.46M). IDYA has less debt than REGN: IDYA (26M) vs REGN (2.71B). REGN has higher revenues than IDYA: REGN (14.1B) vs IDYA (7M).
IDYAREGNIDYA / REGN
Capitalization1.85B52.2B4%
EBITDA-356.46M5.53B-6%
Gain YTD-17.977-31.73557%
P/E RatioN/A12.28-
Revenue7M14.1B0%
Total Cash693MN/A-
Total Debt26M2.71B1%
FUNDAMENTALS RATINGS
IDYA vs REGN: Fundamental Ratings
IDYA
REGN
OUTLOOK RATING
1..100
163
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
4553
PRICE GROWTH RATING
1..100
6065
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for IDYA (61) in the null industry. This means that REGN’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (64) in the null industry is somewhat better than the same rating for REGN (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than REGN’s over the last 12 months.

IDYA's SMR Rating (45) in the null industry is in the same range as REGN (53) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REGN’s over the last 12 months.

IDYA's Price Growth Rating (60) in the null industry is in the same range as REGN (65) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (97) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that REGN’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAREGN
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
56%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
66%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 17 days ago
61%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 2 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IFTAX12.45N/A
N/A
Voya International High Div Low Vol A
FOCPX20.81N/A
N/A
Fidelity OTC
MSTFX11.22N/A
N/A
Morningstar International Equity
FOBAX20.08-0.06
-0.30%
Tributary Balanced Instl
CGIOX47.08-0.19
-0.40%
Calamos Growth and Income R6

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with CRNX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-0.60%
CRNX - REGN
43%
Loosely correlated
+0.78%
ROIV - REGN
43%
Loosely correlated
-0.31%
IDYA - REGN
43%
Loosely correlated
-2.50%
COGT - REGN
40%
Loosely correlated
-2.59%
NTLA - REGN
40%
Loosely correlated
-0.26%
More